MAP2K7 and colorectal carcinoma: We then hypothesized that combination approaches targeting Wnt signaling (Wnt inhibitor, LGK974) and MEK/ERK (MEK inhibitor, trametinib) pathways may have a better synergistic efficacy in treating EIF3H-high CRC.